MRK

SEC source: 0001225208-09-021809 · doc4.xml · derivative · entry 6

WEEKS WENDELL P · CIK 0001206158 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2016-04-27

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021809 · doc4.xml · derivative · entry 5

WEEKS WENDELL P · CIK 0001206158 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2015-04-28

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021809 · doc4.xml · derivative · entry 4

WEEKS WENDELL P · CIK 0001206158 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2014-04-29

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021809 · doc4.xml · derivative · entry 3

WEEKS WENDELL P · CIK 0001206158 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,741.6471

Underlying: Common Stock · 21,741.6471 shares

Expires not disclosed

F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

SEC source: 0001225208-09-021809 · doc4.xml · nonDerivative · entry 2

WEEKS WENDELL P · CIK 0001206158 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · As Custodian

Disclosed balance after: 100

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-021809 · doc4.xml · nonDerivative · entry 1

WEEKS WENDELL P · CIK 0001206158 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 8

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2019-04-30

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 7

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2018-04-29

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 6

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2017-04-26

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 5

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2016-04-27

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 4

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2015-04-28

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 3

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2014-04-29

F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021810 · doc4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,837.907

Underlying: Common Stock · 22,837.907 shares

Expires not disclosed

F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

SEC source: 0001225208-09-021810 · doc4.xml · nonDerivative · entry 1

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-021811 · doc4.xml · derivative · entry 5

JACOBSON HARRY R · CIK 0001255835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2019-04-30

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021811 · doc4.xml · derivative · entry 4

JACOBSON HARRY R · CIK 0001255835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2018-04-29

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021811 · doc4.xml · derivative · entry 3

JACOBSON HARRY R · CIK 0001255835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,211.4175

Underlying: Common Stock · 4,211.4175 shares

Expires not disclosed

F3 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F3 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F3 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

SEC source: 0001225208-09-021811 · doc4.xml · nonDerivative · entry 2

JACOBSON HARRY R · CIK 0001255835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021811 · doc4.xml · nonDerivative · entry 1

JACOBSON HARRY R · CIK 0001255835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,829

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-021812 · doc4.xml · nonDerivative · entry 2

Thompson Craig B. · CIK 0001423419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,352

F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021812 · doc4.xml · nonDerivative · entry 1

Thompson Craig B. · CIK 0001423419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,814

F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021825 · doc4.xml · derivative · entry 2

RUSSO PATRICIA F · CIK 0001023219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,514.21 shares

Expires not disclosed

F2 · derivative.exercise_price: Each unit was the economic equivalent of one share of Schering-Plough Corporation common stock.

F3 · price: In connection with the Transactions, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan.

F3 · derivative.exercise_date: In connection with the Transactions, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan.

F3 · derivative.expiration_date: In connection with the Transactions, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan.

SEC source: 0001225208-09-021825 · doc4.xml · nonDerivative · entry 1

RUSSO PATRICIA F · CIK 0001023219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,148

F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021837 · doc4.xml · derivative · entry 3

KIDDER C ROBERT · CIK 0001179703 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,182.63 shares

Expires not disclosed

F3 · derivative.exercise_price: Each unit was the economic equivalent of one share of Schering-Plough Corporation common stock.

F4 · price: In connection with the Transactions, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan.

F4 · derivative.exercise_date: In connection with the Transactions, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan.

F4 · derivative.expiration_date: In connection with the Transactions, the cash value of the units became payable to the reporting person in accordance with the terms of the 2006 Directors Compensation Plan.

SEC source: 0001225208-09-021837 · doc4.xml · nonDerivative · entry 2

KIDDER C ROBERT · CIK 0001179703 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,022

F2 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.

SEC source: 0001225208-09-021837 · doc4.xml · nonDerivative · entry 1

KIDDER C ROBERT · CIK 0001179703 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,318

F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 11

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,008

Underlying: Common Stock · 5,192 shares

Expires 2016-04-30

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 10

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,738

Underlying: Common Stock · 5,262 shares

Expires 2015-04-30

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 9

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,107

Underlying: Common Stock · 7,893 shares

Expires 2014-04-30

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 8

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,422

Underlying: Common Stock · 6,578 shares

Expires 2013-05-18

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 7

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,246

Underlying: Common Stock · 1,754 shares

Expires 2015-04-24

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 6

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,246

Underlying: Common Stock · 1,754 shares

Expires 2014-02-22

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 5

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,160

Underlying: Common Stock · 11,840 shares

Expires 2013-07-01

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 4

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,776

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 3

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,844

F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,991

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,436

F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 13

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,098

Underlying: Common Stock · 2,702 shares

Expires 2016-04-30

F14 · derivative.exercise_price: The option price for the grant expiring 4/30/16 will convert from $22.91 to 25.11.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 12

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,369

Underlying: Common Stock · 2,631 shares

Expires 2015-04-30

F13 · derivative.exercise_price: The option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 11

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,615

Underlying: Common Stock · 4,385 shares

Expires 2014-04-30

F12 · derivative.exercise_price: The option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 10

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,176

Underlying: Common Stock · 4,824 shares

Expires 2013-05-18

F11 · derivative.exercise_price: The option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 9

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,738

Underlying: Common Stock · 5,262 shares

Expires 2015-04-24

F10 · derivative.exercise_price: The option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 8

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,738

Underlying: Common Stock · 5,262 shares

Expires 2014-02-22

F9 · derivative.exercise_price: The option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 7

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,168

Underlying: Common Stock · 2,132 shares

Expires 2012-02-24

F8 · derivative.exercise_price: The option price for the grant expiring 2/24/12 will convert from $34.68 to $38.01.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 6

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,133

Underlying: Common Stock · 1,467 shares

Expires 2011-02-25

F7 · derivative.exercise_price: The option price for the grant expiring 2/25/11 will convert from $40.05 to $43.90.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 5

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,861

Underlying: Common Stock · 6,139 shares

Expires 2011-01-01

F4 · derivative.exercise_price: The option price for the grant expiring 1/01/11 will convert from $54.25 to $59.47.

F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 4

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By 401(k)

Disclosed balance after: 3,377.3284

F3 · price: Received as part of the Agreement and Plan of Merger by and among, inter alia, Merck Sharp & Dohme Corp. and Merck & Co., Inc. (formerly Schering-Plough Corporation) in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. common stock held under the Merck Sharp & Dohme Corp. 401(k) plan.

SEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 3

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · As Custodian

Disclosed balance after: 252

F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.

SEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 2

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,855

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 1

Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,503

F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.